NEW YORK (GenomeWeb) – Thermo Fisher Scientific announced today that it is partnering with West China Hospital of Sichuan University to jointly develop a platform to research precision medicine.
Under the terms of the agreement, the partners will build centers to train people as pathologic diagnosticians and to implement standardized pathology quality control. They will also develop advanced laboratories. West China Hospital said in a statement that it is aiming to become a national center for biomedical research.
Financial terms of the deal were not disclosed.
The deal is the latest personalized medicine-related partnership for Thermo Fisher. Earlier this month, the firm announced it would provide sequencing technology for tumor sequencing firm Strata Oncology. And over the last year, Thermo Fisher has signed companion diagnostic partnerships with Novartis and Pfizer, as well as a technology partnership with Pfizer for that firm's Chilean Center of Excellence in Precision in Medicine.